Company profile: Qpex Biopharma
1.1 - Company Overview
Company description
- Provider of antibiotic agents addressing critical needs in infectious disease treatment and antimicrobial resistance for inpatient and outpatient care. Portfolio includes QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor; OMNIvance (Xeruborbactam + Meropenem) for gram-negative infections; ORAvance, an oral Xeruborbactam prodrug enhancing oral beta-lactams; and QPX9003, a lipopeptide for MDR gram-negative pathogens.
Products and services
- OMNIvance: A combination therapy pairing the beta-lactamase inhibitor Xeruborbactam with Meropenem to treat infections caused by gram-negative bacteria
- ORAvance: Oral prodrug formulation of the beta-lactamase inhibitor Xeruborbactam designed to enhance the activity of oral beta-lactam antibiotics against resistant bacteria
- QPX7728: Ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of multiple beta-lactam antibiotics against resistant Enterobacterales and other pathogens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Qpex Biopharma
Stat-Sure Diagnostics
HQ: United States
Website
- Description: Provider of diagnostic testing specializing in HIV.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stat-Sure Diagnostics company profile →
Fluoresentric
HQ: United States
Website
- Description: Provider of assay design, optimization, and custom manufacturing services for the healthcare and biotechnology sector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluoresentric company profile →
Spring Bank Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule nucleic acid hybrid-based therapeutics and immuno-oncology candidates, including FS118, a LAG-3/PD-L1 mAb2 bispecific antibody in Phase 2 for head and neck cancer, NSCLC and DLBCL; FS120, an OX40/CD137 dual agonist mAb2 in Phase 1; FS222, a CD137/PD-L1 mAb2 in Phase 1 for PD-L1-low tumors; and SB 11285, an IV second-generation STING agonist in Phase 1, alone and with atezolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spring Bank Pharmaceuticals company profile →
Evaxion Biotech
HQ: Denmark
Website
- Description: Provider of AI-immunology™ platform-driven immunotherapies for cancer and infectious diseases, including EVX-01, a Phase 2 personalized cancer vaccine targeting patient-specific tumor antigens, and EVX-B1, a vaccine antigen against Staphylococcus Aureus, plus models PIONEER™, ObsERV™, and AI-DEEP™ for vaccine design and CPI response prediction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evaxion Biotech company profile →
Earth Science Tech
HQ: United States
Website
- Description: Provider of science-based biotechnology offerings bringing Nature's Pharmacy to the public, operating RxCompoundStore, a Miami compounding pharmacy licensed in 23 states; Peaks Curative, a telemedicine platform for men's and women's health offering ED products via a proprietary tadalafil gummy; Avenvi, a Miami real estate development firm; and Mister Meds, a Texas wellness-focused pharmacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Earth Science Tech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Qpex Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Qpex Biopharma
2.2 - Growth funds investing in similar companies to Qpex Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Qpex Biopharma
4.2 - Public trading comparable groups for Qpex Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →